Bristol-Myers, Celgene pair an immuno-oncology star with a rising chemotherapy

Damian Garde

Bristol-Myers Squibb and are joining forces on a cancer combination treatment, testing the former's highly anticipated immunotherapy in tandem with an on-the-market chemo drug against a host of tumor targets.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS